AbbVie Inc. ABBV
AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B |
| Cost of revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B | $7.72B | $7.04B | $5.83B |
| Gross profit | $42.96B | $39.43B | $33.90B | $40.64B | $38.75B | $30.42B | $25.83B | $25.04B | $21.17B | $19.81B |
| SG&A | $14.01B | $14.75B | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B | $7.40B | $6.29B | $5.88B |
| Total operating expenses | $46.09B | $47.20B | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B | $26.37B | $18.67B | $16.30B |
| Operating income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B |
| Interest expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B | $1.35B | $1.15B | $1.05B |
| Pre-tax income | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B | $5.20B | $7.73B | $7.88B |
| Income tax | $2.36B | $570.0M | $1.38B | $1.63B | $1.44B | $1.22B | $544.0M | $490.0M | $2.42B | $1.93B |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B |
| EPS, basic | 2.37 | 2.40 | 2.73 | 6.65 | 6.48 | 2.73 | 5.30 | 3.67 | 3.31 | 3.65 |
| EPS, diluted | 2.36 | 2.39 | 2.72 | 6.63 | 6.45 | 2.72 | 5.28 | 3.66 | 3.30 | 3.63 |
| Shares, diluted (wtd. avg.) | $1.77B | $1.77B | $1.77B | $1.78B | $1.78B | $1.67B | $1.48B | $1.55B | $1.60B | $1.63B |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B | $7.29B | $9.30B | $5.10B |
| Short-term investments | $28.0M | $31.0M | $2.0M | $28.0M | $84.0M | $30.0M | $0 | $772.0M | $486.0M | $1.32B |
| Receivables | $12.59B | $10.92B | $11.15B | $11.25B | $9.98B | $8.82B | $5.43B | $5.38B | $5.09B | — |
| Inventory | $4.95B | $4.18B | $4.10B | $3.58B | $3.13B | $3.31B | $1.81B | $1.60B | $1.60B | $1.44B |
| Total current assets | $29.06B | $25.58B | $33.00B | $28.46B | $27.93B | $24.17B | $49.52B | $16.95B | $21.22B | $16.19B |
| Property, plant and equipment | $5.63B | $5.13B | $4.99B | $4.93B | $5.11B | $5.25B | $2.96B | $2.88B | $2.80B | $2.60B |
| Goodwill | $35.64B | $34.96B | $32.29B | $32.16B | $32.38B | $33.12B | $15.60B | $15.66B | $15.79B | $15.42B |
| Other intangibles | $52.64B | $60.07B | $55.61B | $67.44B | $75.95B | $82.88B | $18.65B | $21.23B | $27.56B | $28.90B |
| Total assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B | $59.35B | $70.79B | $66.10B |
| Accounts payable | $3.59B | $2.94B | $3.69B | $2.93B | $2.88B | $2.28B | $1.45B | $1.55B | $1.47B | $1.41B |
| Short-term debt | $2.50B | $0 | $0 | $1.0M | $14.0M | $34.0M | $0 | $3.70B | $400.0M | $377.0M |
| Total current liabilities | $43.29B | $38.75B | $37.84B | $29.54B | $35.19B | $28.66B | $15.59B | $17.24B | $16.64B | $9.78B |
| Long-term debt | $64.50B | $66.84B | $59.24B | $63.13B | $75.96B | $84.95B | $67.23B | — | — | — |
| Retained earnings | -$15.49B | -$7.90B | -$1.00B | $4.78B | $3.13B | $1.05B | $4.72B | $3.37B | $5.46B | $4.38B |
| Total equity | -$3.27B | $3.33B | $10.40B | $17.29B | $15.44B | $13.10B | -$8.17B | -$8.45B | $5.10B | $4.64B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B | $13.43B | $9.96B | $7.04B |
| Depreciation and amortisation | $762.0M | $764.0M | $752.0M | $778.0M | $803.0M | $666.0M | $464.0M | $471.0M | $425.0M | $425.0M |
| Stock-based compensation | $955.0M | $911.0M | $747.0M | $671.0M | $692.0M | $753.0M | $430.0M | $421.0M | $365.0M | $353.0M |
| Capital expenditure | $1.21B | $974.0M | $777.0M | $695.0M | $787.0M | $798.0M | $552.0M | $638.0M | $529.0M | $479.0M |
| Investing cash flow | -$6.64B | -$20.82B | -$2.01B | -$623.0M | -$2.34B | -$37.56B | $596.0M | -$1.01B | -$274.0M | -$6.07B |
| Financing cash flow | -$12.72B | -$5.21B | -$17.22B | -$24.80B | -$19.04B | -$11.50B | $18.71B | -$14.40B | -$5.51B | -$3.93B |
| Dividends paid | $11.66B | $11.03B | $10.54B | $10.04B | $9.26B | $7.72B | $6.37B | $5.58B | $4.11B | $3.72B |
| Buybacks | $980.0M | $1.71B | $1.97B | $1.49B | $934.0M | $978.0M | $629.0M | $12.01B | $1.41B | $6.03B |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001551152-26-000008.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $138.42B | 35.6x | 8.9% |